News · 26 weeks36-100%
2026-04-192026-10-11
Mix1590d
- SEC Filings8(53%)
- Earnings4(27%)
- Analyst2(13%)
- Other1(7%)
Latest news
25 items- ANALYSTCellectis downgraded by Barclays with a new price targetBarclays downgraded Cellectis from Overweight to Underweight and set a new price target of $1.30
- ANALYSTCellectis downgraded by CitizensCitizens downgraded Cellectis from Mkt Outperform to Mkt Perform
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Announces Strategic Transformation To In Vivo Gene Editing CompanyCellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel developmentRealignment of the operating model targeting Cellectis cash runway extension into H2 2028Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Cellectis S.A.6-K/A - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateNEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update. Conference Call and Webcast Details: September 14, 2026 English-language at 8:00 a.m. ET. / 2:00 p.m. CET Webcast link:https://viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480Phone number: +1 (800) 717 1738 or +1 (646) 307 1865France Toll Free: +33 (800) 945 120 French-language at 9:00 a.m. ET. / 3:00 p.m. CET Webcast link:https://viavi
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Announces Participation in Upcoming Investor ConferencesNEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference – Boston, MASeptember 10, 2026 Baird 2026 Global Healthcare Conference – New YorkSeptember 15, 2026Company presentation at 12:50 - 1:20 p.m. ET Fall Focus: Barclays Biotech 1x1 Day – New YorkOctober 6, 2026 Stifel 2026 Healthcare Conference – New YorkNovember 10-12, 2026 Jefferies Global Healthcare Conference – LondonNovember 16-19, 2026 Cellectis'
- SECSEC Form S-8 filed by Cellectis S.A.S-8 - Cellectis S.A. (0001627281) (Filer)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Reports Financial Results for the Second Quarter 2026Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim analysis expected in Q4 2026 Eti-cel: Phase 1 in r/r NHL (NATHALI-01) Translational data from the NATHALI-01 trial highlighting key drivers of response presented at EHA 2026Full Phase 1 dataset expected in Q4 2026 Cash, cash equivalents and fixed-term deposits of $169 million as of June 30, 20261 provide runway into Q4 2027. NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Report Second Quarter Financial Results on August 6, 2026NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com About Cellectis
- PRProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioEMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer. The appointments deepen the company’s leadership bench as Prolynx advances multiple ultra-long-acting candidates for obesity and related metabolic diseases toward IND-enabling studies. "We believe long-acting agents with the potential to be dosed on a monthly or quarterly basis represent one of the most important next frontiers for the l
- SECAmendment: SEC Form 6-K/A filed by Cellectis S.A.6-K/A - Cellectis S.A. (0001627281) (Filer)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Reports Results from Shareholders Meeting Held on June 25, 2026NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis’ website:https://www.cellectis.com/en/investors/g
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressNEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating la
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALLNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The granting of RMAT designation reflects the FDA's recognition of the potential for lasme-cel to address the unmet medical need fac
- ANALYSTBarclays initiated coverage on Cellectis with a new price targetBarclays initiated coverage of Cellectis with a rating of Overweight and set a new price target of $9.00
CLLS FAQ
7 questionsWhat does Cellectis S.A. do?
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma...Where does CLLS stock trade?
Cellectis S.A. (CLLS) is listed on NASDAQ.What sector and industry is CLLS in?
Cellectis S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cellectis S.A. go public?
Cellectis S.A. (CLLS) completed its IPO in 2015.What are analysts saying about CLLS?
Cellectis S.A. has had 8 recent analyst actions on file. The most recent action was from Barclays: Underweight with a $130.00 price target on 2026-09-16.What companies are similar to CLLS?
Notable peers in the same industry include ALLO (Allogene Therapeutics Inc.), PSTX (Poseida Therapeutics Inc.), CLXT (Calyxt Inc.). Compare CLLS side-by-side with any of them on Quantisnow.How can I track CLLS on Quantisnow?
Quantisnow aggregates Cellectis S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLLS to receive live email and push alerts on every new disclosure.